PER—
PBR—
EPS—
BPS—
Dividend yield—
Market cap—
Value traded—
08-31Buy · ₩2,000,000Daishin Securities: ₩3tn capital increase, financing considering mid-to-long-term investment plans07-24Buy · ₩2,000,000Meritz Securities: 2Q26P Review: Peptide plant acquisition is positive, order confirmation needed07-24Buy · ₩2,000,000Daishin Securities: Record quarterly earnings; growth continues despite 3Q pause07-24Buy · ₩1,900,000iM Securities: A new growth narrative has emerged07-24Buy · ₩2,090,000IBK Securities: US production base, Plant 5, and peptides